Skip to content

Concord Biotech hits 52-week high after Jefferies initiates #39;buy#39; call; sees 19% upside

Jefferies also prefers Concord Biotech over its peer Glenmark Life Sciences due to its superior growth profile, strong execution track record, industry-leading margins, and favourable return ratios.

Read More

​ Jefferies also prefers Concord Biotech over its peer Glenmark Life Sciences due to its superior growth profile, strong execution track record, industry-leading margins, and favourable return ratios. Jefferies also prefers Concord Biotech over its peer Glenmark Life Sciences due to its superior growth profile, strong execution track record, industry-leading margins, and favourable return ratios.  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish